Jun 20 |
Kyverna gains as FDA clears trial for lead therapy
|
Jun 20 |
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
|
Jun 17 |
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
|
Jun 14 |
Kyverna stock plunges 28% amid data update on lead drug
|
Jun 14 |
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
|
Jun 10 |
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
|
Jun 7 |
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
|
May 15 |
Kyverna Therapeutics reports Q1 GAAP EPS of -$1.12
|
May 14 |
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
|
Apr 29 |
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|